Potent Proteasome Inhibitors Derived from the Unnatural cis-Cyclopropane Isomer of Belactosin A: Synthesis, Biological Activity, and Mode of Action

Journal of Medicinal Chemistry
2013.0

Abstract

The natural product belactosin A (1) with a trans-cyclopropane structure is a useful prototype compound for developing potent proteasome (core particle, CP) inhibitors. To date, 1 and its analogues are the only CP ligands that bind to both the nonprimed S1 pocket as well as the primed substrate binding channel; however, these molecules harbor a high IC50 value of more than 1 μM. We have performed structure-activity relationship studies, thereby elucidating unnatural cis-cyclopropane derivatives of 1 that exhibit high potency to primarily block the chymotrypsin-like active site of the human constitutive (cCP) and immunoproteasome (iCP). The most active compound 3e reversibly inhibits cCP and iCP similarly with an IC50 of 5.7 nM. X-ray crystallographic analysis of the yeast proteasome in complex with 3e revealed that the ligand is accommodated predominantly into the primed substrate binding channel and covalently binds to the active site threonine residue via its β-lactone ring-opening.

Knowledge Graph

Similar Paper

Potent Proteasome Inhibitors Derived from the Unnatural cis-Cyclopropane Isomer of Belactosin A: Synthesis, Biological Activity, and Mode of Action
Journal of Medicinal Chemistry 2013.0
Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates
Journal of Medicinal Chemistry 2014.0
Affinity labeling of the proteasome by a belactosin A derived inhibitor
Bioorganic & Medicinal Chemistry Letters 2008.0
A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay
Biochemical Pharmacology 2004.0
Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors
Bioorganic & Medicinal Chemistry Letters 2009.0
New betulinic acid derivatives as potent proteasome inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
C1 and N5 derivatives of cerpegin: Synthesis of a new series based on structure–activity relationships to optimize their inhibitory effect on 20S proteasome
Bioorganic & Medicinal Chemistry Letters 2013.0
Cystargolides, 20S Proteasome Inhibitors Isolated from <i>Kitasatospora cystarginea</i>
Journal of Natural Products 2015.0
Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea
Journal of Natural Products 2015.0
Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome
Bioorganic &amp; Medicinal Chemistry Letters 2005.0